Stem Cell Transplantation for Hematological Malignancies
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This protocol using busulfan, cyclophosphamide and melphalan has been designed as
conditioning therapy for patients receiving stem cell transplantation for acute leukemia or
myelodysplastic syndrome (MDS). The hypothesis is that this new regimen will be well
tolerated and will cure the patient.